PT
● MODULE 10 / 20
Hemostasis, Thrombosis & Anemia
Distinguish platelet inhibition, anticoagulation, thrombolysis and replacement of hematinic deficiencies.
Quick revision ↓ Medical Dictionary
FULL CHAPTER EXPLANATION
Deep Learning — Module 10
Read this section in sequence. It moves from drug targets to therapeutic effects, adverse reactions and safe use.
01
Platelets and coagulation
Platelet activation drives primary hemostasis; the coagulation cascade generates thrombin and fibrin to stabilize clot. Aspirin reduces platelet thromboxane production, while clopidogrel and related agents inhibit platelet ADP signaling at P2Y12 receptors. Their effects differ from anticoagulants that reduce coagulation-factor activity. Antiplatelet and anticoagulant drugs are not interchangeable merely because both reduce thrombosis. Combining them can increase bleeding and requires a clear indication.
02
Heparins and oral anticoagulants
Unfractionated heparin enhances antithrombin action against thrombin and factor Xa. Low-molecular-weight heparins have proportionately greater anti-Xa activity. Warfarin inhibits vitamin K recycling, reducing synthesis of functional vitamin-K-dependent factors; its delayed onset and many interactions explain INR monitoring. Direct oral anticoagulants inhibit factor Xa or thrombin, depending on the drug. Their renal handling, indication restrictions and interactions differ, and INR is not a universal measure of their effect.
03
Bleeding, thrombocytopenia and reversal
Bleeding assessment considers site, severity, last dose, renal function and concomitant medicines. Protamine reverses unfractionated heparin and only partially reverses some low-molecular-weight effects. Warfarin reversal may require vitamin K and rapid factor replacement according to urgency. Immune heparin-induced thrombocytopenia is paradoxically prothrombotic; a falling platelet count does not imply protection from clotting. Reversal agents and alternative anticoagulants require drug-specific protocols rather than one class-wide rule.
04
Fibrinolysis and antifibrinolysis
Alteplase promotes conversion of plasminogen to plasmin and can dissolve fibrin in selected time-sensitive thrombotic conditions. Major bleeding, including intracranial hemorrhage, is a central risk; eligibility depends on diagnosis and contraindications. Tranexamic acid inhibits fibrinolysis by interfering with plasminogen binding and is used for selected bleeding indications. Neither strategy substitutes for source control or treatment of the underlying cause.
05
Hematinics and erythropoiesis
Iron replacement treats iron deficiency, but the cause of deficiency must also be investigated. Oral iron can cause gastrointestinal symptoms; parenteral preparations have distinct administration and safety requirements. Vitamin B12 deficiency can cause neurological injury, and folate alone may improve the anemia while neurological disease persists. Erythropoiesis-stimulating agents act on marrow precursors and require adequate iron availability; thrombosis and hypertension are important risks. Transfusion and replacement therapy serve different clinical purposes.
High-Yield Revision
- Antiplatelets, anticoagulants and fibrinolytics act at different stages.
- Heparin-induced thrombocytopenia can cause thrombosis.
- Investigate the cause of anemia rather than treating the number alone.
Common Exam & Concept Pitfalls
- INR does not quantify every anticoagulant effect.
- Folate alone can obscure the hematologic presentation of B12 deficiency.
Sources & Further Reading
Curriculum scope checked 23 September 2026. These original study notes summarize established principles; current institutional guidance and product information govern clinical use. Faculty review is pending.
RAHBAR study structure: target → drug action → therapeutic use → adverse effects → monitoring. Use institutional curriculum and faculty guidance for local sequencing, practical requirements and assessment specifications.